Igel-Egalon Angélique

Dr. Igel-Egalon Angélique

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Pathogens
Verified
Journal Article
Open access
PDF file
IAIgel-Egalon Angélique
Igel-Egalon Angélique
VBVincent Beringue
Vincent Beringue
HRHuman Rezaei
Human Rezaei
PSPierre Sibille
Pierre Sibille
Several experimental evidences show that prions are non-conventional pathogens, which physical support consists only in proteins. This finding raised questions regarding the observed prion strain-to-strain variations and the species barrier that happened to be crossed with dramatic consequences on human health and veterinary policies during the last 3 decades. This review presents a focus on a few advances in the field of prion structure and prion strains characterization: from the historical approaches that allowed the concept of prion strains to emerge, to the last results demonstrating that a prion strain may in fact be a combination of a few quasi species with subtle biophysical specificities. Then, we will focus on the current knowledge on the factors that impact species barrier strength and species barrier crossing. Finally, we present probable scenarios on how the interaction of strain properties with host characteristics may account for differential selection of new conformer variants and eventually species barrier crossing.

7 September 2017 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
IAIgel-Egalon Angélique
Igel-Egalon Angélique
MMMohammed Moudjou
Mohammed Moudjou
DMDavy Martin
Davy Martin
ABAlexandra Busley
Alexandra Busley
TKTina Knäpple
Tina Knäpple
HRHuman Rezaei
Human Rezaei
Mammalian prions, the pathogens that cause transmissible spongiform encephalopathies, propagate by self-perpetuating the structural information stored in the abnormally folded, aggregated conformer (PrPSc) of the host-encoded prion protein (PrPC). To date, no structural model related to prion assembly organization satisfactorily describes how strain-specified structural information is encoded and by which mechanism this information is transferred to PrPC. To achieve progress on this issue, we correlated the PrPSc quaternary structural transition from three distinct prion strains during unfolding and refolding with their templating activity. We reveal the existence of a mesoscopic organization in PrPSc through the packing of a highly stable oligomeric elementary subunit (suPrP), in which the strain structural determinant (SSD) is encoded. Once kinetically trapped, this elementary subunit reversibly loses all replicative information. We demonstrate that acquisition of the templating interface and infectivity requires structural rearrangement of suPrP, in concert with its condensation. The existence of such an elementary brick scales down the SSD support to a small oligomer and provide a basis of reflexion for prion templating process and propagation. Prions are self-propagating assemblies with all necessary and sufficient replicative information stored in the 3D structure of the misfolded form of PrP called PrPSc. Since the emergence of the prion theory in the 80s, many attempts have been done to identify prion replicative information at molecular scale. Different models have been constructed based on a broad panel of experimental observations and some of them predict the existence of periodic elements constituting prion assemblies. Here, by using partial unfolding approaches, we trapped an oligomeric conformer that we called suPrP, which could constitute the elementary brick of prion assemblies. Once isolated, this elementary brick is devoid of infectivity. However, it becomes infectious once condensated into larger assemblies. The identification of the elementary PrP building block provides a new structural basis for understanding prion replicative information storage and spreading.

1 December 2013 in Journal of Hospital Infection
Verified
Journal Article
Closed access
GMG. McDonnell
G. McDonnell
CDC. Dehen
C. Dehen
APA. Perrin
A. Perrin
VTV. Thomas
V. Thomas
IAIgel-Egalon Angélique
Igel-Egalon Angélique
ECE. Comoy
E. Comoy

10 May 2019 in Viruses
Verified
Journal Article
Open access
PDF file
IAIgel-Egalon Angélique
Igel-Egalon Angélique
JBJan Bohl
Jan Bohl
MMMohammed Moudjou
Mohammed Moudjou
LHLaetitia Herzog
Laetitia Herzog
FRFabienne Reine
Fabienne Reine
VBVincent Beringue
Vincent Beringue
Prions are proteinaceous infectious agents responsible for a range of neurodegenerative diseases in animals and humans. Prion particles are assemblies formed from a misfolded, β-sheet rich, aggregation-prone isoform (PrPSc) of the host-encoded cellular prion protein (PrPC). Prions replicate by recruiting and converting PrPC into PrPSc, by an autocatalytic process. PrPSc is a pleiomorphic protein as different conformations can dictate different disease phenotypes in the same host species. This is the basis of the strain phenomenon in prion diseases. Recent experimental evidence suggests further structural heterogeneity in PrPSc assemblies within specific prion populations and strains. Still, this diversity is rather seen as a size continuum of assemblies with the same core structure, while analysis of the available experimental data points to the existence of structurally distinct arrangements. The atomic structure of PrPSc has not been elucidated so far, making the prion replication process difficult to understand. All currently available models suggest that PrPSc assemblies exhibit a PrPSc subunit as core constituent, which was recently identified. This review summarizes our current knowledge on prion assembly heterogeneity down to the subunit level and will discuss its importance with regard to the current molecular principles of the prion replication process.

11 August 2018 in Journal of Mathematical Biology
Verified
Journal Article
Closed access
PDF file
MHMohamed HELAL
Mohamed HELAL
IAIgel-Egalon Angélique
Igel-Egalon Angélique
ALAbdelkader Lakmeche
Abdelkader Lakmeche
PMPauline Mazzocco
Pauline Mazzocco
APAngélique Perrillat-Mercerot
Angélique Perrillat-Mercerot
LTLéon M. Tine
Léon M. Tine

1 December 2020 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
MMMohammed Moudjou
Mohammed Moudjou
JCJohan Castille
Johan Castille
BPBruno Passet
Bruno Passet
LHLaetitia Herzog
Laetitia Herzog
FRFabienne Reine
Fabienne Reine
IAIgel-Egalon Angélique
Igel-Egalon Angélique
Prions are pathogenic infectious agents responsible for fatal, incurable neurodegenerative diseases in animals and humans. Prions are composed exclusively of an aggregated and misfolded form (PrPSc) of the cellular prion protein (PrPC). During the propagation of the disease, PrPScrecruits and misfolds PrPCinto further PrPSc. In human, iatrogenic prion transmission has occurred with incompletely sterilized medical material because of the unusual resistance of prions to inactivation. Most commercial prion disinfectants validated against the historical, well-characterized laboratory strain of 263K hamster prions were recently shown to be ineffective against variant Creutzfeldt-Jakob disease human prions. These observations and previous reports support the view that any inactivation method must be validated against the prions for which they are intended to be used. Strain-specific variations in PrPScphysico-chemical properties and conformation are likely to explain the strain-specific efficacy of inactivation methods. Animal bioassays have long been used as gold standards to validate prion inactivation methods, by measuring reduction of prion infectivity. Cell-free assays such as the real-time quaking-induced conversion (RT-QuIC) assay and the protein misfolding cyclic amplification (PMCA) assay have emerged as attractive alternatives. They exploit the seeding capacities of PrPScto exponentially amplify minute amounts of prions in biospecimens. European and certain national medicine agencies recently implemented their guidelines for prion inactivation of non-disposable medical material; they encourage or request the use of human prions and cell-free assays to improve the predictive value of the validation methods. In this review, we discuss the methodological and technical issues regarding the choice of (i) the cell-free assay, (ii) the human prion strain type, (iii) the prion-containing biological material. We also introduce a new optimized substrate for high-throughput PMCA amplification of human prions bound on steel wires, as translational model for prion-contaminated instruments.